Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children

Inclusion Criteria: * have a height less than two standard deviations (SD) below the median height for individuals of the same age or height, a growth velocity (GV) ≤4 cm/yr, a GH peak concentration \<7 ng/ml in two different provocative tests, a bone age (BA; ≤9 years in girls and ≤10 years in boys) at least 2 years less than his/her chronological age (CA); * be in preadolescence (Tanner stage 1) and have a CA \>3 years; * have a height value recorded 3 months before the start of GH treatment to calculate pre-treatment GV; * receive no prior GH treatment. * sign informed consent Exclusion Criteria: * patients with severe cardiopulmonary * patients with hematological diseases * a current or past history of malignant tumors * immunodeficiency diseases * mental diseases * patients positive for hepatitis B e-antibody (HBeAb) * hepatitis B surface antigen (HBsAg) * hepatitis B e antigen (HBeAg) * patients with other growth disorders, such as Turner syndrome * constitutional delay of growth and puberty, and Laron syndrome